Adjuvant Chemotherapy Guided by a 21‑Gene Expression Assay in Breast Cancer
Endocrine therapy was noninferior to chemoendocrine therapy in the analysis of invasive disease‑free survival for women with hormone‑receptor‑positive, HER2‑negative, axillary node‑negative breast cancer who had a mid‑range 21‑gene recurrence score of 11 to 25.
This trial clarifies whether adjuvant chemotherapy provides a survival advantage in patients with a mid‑range Oncotype DX score, potentially sparing many women from unnecessary treatment and its associated toxicity.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC